Watching CytoDyn Inc.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planCytoDyn Inc.
AI Executive Summary
AI-powered analysis of 10-K filing content
CytoDyn remains a pre-revenue, clinical-stage biotech with a going concern opinion, low cash reserves, and a history of significant operating losses. The company has pivoted its lead asset, leronlimab, away from its historical HIV/COVID-19 focus toward solid-tumor oncology indications (colorectal and triple-negative breast cancer), while writing off previously capitalized pre-launch inventory. Ongoing shareholder litigation (with a settlement in principle not yet finalized) and continued reliance on dilutive/uncertain financing add to elevated risk.
Red Flags Detected (7)
Going concern opinion issued by auditors
Low cash reserves with no substantial revenue expected for the foreseeable future
Write-off of previously capitalized pre-launch inventories of leronlimab and related raw materials
4 more red flags detected
Key Takeaways
Company remains entirely dependent on future capital raises to fund operations and clinical trials
Lead product leronlimab has yet to gain any regulatory approval despite years of development history dating to 2012 acquisition from Progenics
3 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.